Network Meta-Analysis Comparing Efficacy and Safety Outcomes of Atogepant, Rimegepant, and Galcanezumab in Patients with Episodic Migraine After Including CHALLENGE-MIG Trial (P9-12.007)
Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available
10.1212/wnl.0000000000210714